Drugs / Atropine
Atropine
also known as
atropine sulfate · Atropine Sulphate · Alleance · ATR · Atroject · Atropen · Atrophate · Atropine (autoinjector) · +35 more
Other / unclassified targets CHRM1, CHRM2, CHRM3 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Atropine sulfate FGK | — | 2025-11-21 | europa.eu ↗ |
| Approved | EU (EMA) | Ryjunea | — | 2025-06-02 | europa.eu ↗ |
| Label expansion | US (FDA) | ATROPEN | — | 2003-06-19 | fda.gov ↗ |
| Approved | US (FDA) | LOMOTIL | — | 1960-09-15 | fda.gov ↗ |
Trials 104 · started per year
today
US approved 1960
EU approved 2025
1
1
2
3
1
2
4
1
2
3
3
2
3
3
5
2
6
8
4
7
9
12
7
4
9
19591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT05164367 | Oct 2022 → Jun 2023 | cerebral palsy | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT05199597 | May → Jun 2022 | myopia | Ohio State University | Completed | No outcome recorded |
| Phase 0 | NCT03972683 | Apr 2019 → Jul 2021 | — | Colorado State University | Withdrawn | No outcome recorded |
| Phase 0 | NCT03508817 | Dec 2018 → Jan 2022 | myopia | Sultan Qaboos University | Unknown | No outcome recorded |
| Phase 0 | NCT02823665 | Jul 2015 → Aug 2026 overdue | postgastrectomy syndrome | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 0 | NCT00992901 | Oct 2009 → Aug 2026 overdue | hypoglycemia, postgastrectomy syndrome | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 0 | NCT00689208 | May 2007 → Oct 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT05855018 | May → Jun 2023 | — | Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 1 | NCT05481489 | Feb → Mar 2023 | myopia | Laboratorios Sophia S.A de C.V. | Withdrawn | No outcome recorded |
| Phase 1 | NCT05470881 | Aug → Dec 2022 | myopia | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT07674966 | Mar → Oct 2022 | myopia | University of California, Berkeley | Completed | No outcome recorded |
| Phase 1 | NCT01951729 | Mar 2013 → May 2015 | prediabetes syndrome | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00932256 | Oct 2009 | seasonal allergic rhinitis | Magna Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00457717 | Jul 2005 → Jul 2006 | myopia | China Medical University, China | Completed | No outcome recorded |
| Phase 1 | NCT00251602 | Mar 2003 → Aug 2012 | — | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07449247 | Mar 2026 → Jun 2027 expected | myopia | Tianjin Medical University Eye Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06523504 | Feb 2024 → Mar 2026 overdue | myopia | Ruihua Wei | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03593044 | Jul 2018 → Jan 2019 | myopia | Jeffrey J. Walline, OD PhD | Completed | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT07367178 | Jul 2026 → Jun 2027 expected | hormone receptor-positive breast cancer, triple-negative breast carcinoma | MedSIR | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07676981 | Jun → Jul 2026 overdue | epiphora due to excess lacrimation | Rehan Ahmed | Recruiting | No outcome recorded |
| Phase 2 | NCT06765603 | Feb 2025 → Dec 2028 expected | myopia | Singapore National Eye Centre | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06200194 | Oct 2024 → Jul 2026 overdue | myopia | National Yang Ming Chiao Tung University Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06174935 | Jan → Jun 2024 | vitreous disorder | Jeanette Du | Unknown | No outcome recorded |
| Phase 2 | NCT05815784 | May 2023 → Mar 2026 overdue | myopia | Ann & Robert H Lurie Children's Hospital of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT04391361 | Nov 2020 → Sep 2023 | amyotrophic lateral sclerosis | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03911271 | May 2019 → Apr 2024 | myopia | Line Kessel | Completed | No outcome recorded |
| Phase 2 | NCT03690089 | Apr 2019 → Feb 2024 overdue | myopia | Belfast Health and Social Care Trust | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02082054 | Mar → May 2014 | seasonal allergic rhinitis | Magna Pharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT00121524 | Jan 2003 → May 2008 | cardiac arrest | Petter Andreas Steen | Completed | No outcome recorded |
| Phase 2 | NCT00431392 | Sep 2001 → ? | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT07164092 | Sep 2025 → Sep 2027 expected | myopia | Mansoura University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT03865160 | Oct 2021 → Nov 2025 overdue | myopia | University Eye Hospital, Freiburg | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04173780 | Feb 2020 → May 2024 | myopia | University Hospital, Strasbourg, France | Terminated | No outcome recorded |
| Phase 2/3 | NCT00371124 | Mar 2006 → ? | myopia | Singapore National Eye Centre | Unknown | No outcome recorded |
| Phase 319 trials | ||||||
| Phase 3 | NCT07095894 | Jun 2026 → Dec 2028 expected | myopia | Jaeb Center for Health Research | Recruiting | No outcome recorded |
| Phase 3 | NCT07567040 | May 2026 → May 2028 expected | myopia | Ohio State University | Recruiting | No outcome recorded |
| Phase 3 | NCT07028827 | Sep 2025 → Dec 2027 expected | myopia | Ocus Innovation Ireland Limited | Recruiting | No outcome recorded |
| Phase 3 | NCT06697522 | Jun → Oct 2023 | myopia | Ocumension Therapeutics (Suzhou) Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT05529056 | May 2022 → Jun 2023 | myopia | LitePharmTech Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT06209281 | May 2022 → Aug 2023 overdue | myopia | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04910477 | Jun → Sep 2021 | headache disorder | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT04770610 | Apr 2021 → Mar 2027 expected | myopia | Ocumension (Hong Kong) Limited | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04338373 | Feb 2020 → Aug 2021 | myopia | The V.P. Vyhodcev Eye Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03942419 | Jun 2019 → Oct 2024 | myopia | Eyenovia Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03918915 | Apr 2019 → May 2024 | myopia | Sydnexis, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03334253 | Jun 2018 → Apr 2022 | myopia | Jaeb Center for Health Research | Completed | No outcome recorded |
| Phase 3 | NCT03350620 | Nov 2017 → Sep 2022 | myopia | Vyluma, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02870478 | Jul 2016 → Nov 2019 | myopia | University of California, Berkeley | Completed | No outcome recorded |
| Phase 3 | NCT02194088 | Apr → Nov 2014 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01293201 | Mar → Jun 2011 | seasonal allergic rhinitis | Magna Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00583323 | Feb 2003 → Sep 2005 | lymphoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00094692 | Oct 2002 → Dec 2005 | amblyopia | Jaeb Center for Health Research | Completed | No outcome recorded |
| Phase 3 | NCT00001864 | May 1999 → Nov 2001 | amblyopia, anisometropia, strabismus | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 423 trials | ||||||
| Phase 4 | NCT07434635 | Feb 2026 → Feb 2028 expected | eye disorder | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 4 | NCT06450132 | Aug 2024 → Jun 2026 overdue | myopia | Ohio State University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05892913 | Jul → Oct 2023 | pregnancy disorder | Abant Izzet Baysal University | Completed | No outcome recorded |
| Phase 4 | NCT07406399 | Jun 2023 → Nov 2025 | contact lens corneal edema, myopia | Beijing Tongren Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05065424 | Apr 2022 → Mar 2026 | newborn respiratory distress syndrome | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT05448989 | Jan 2022 → Dec 2023 | myopia | Shanghai Eye Disease Prevention and Treatment Center | Unknown | No outcome recorded |
| Phase 4 | NCT05357326 | Jul 2021 → Jul 2023 | myopia | Shanghai Eye Disease Prevention and Treatment Center | Unknown | No outcome recorded |
| Phase 4 | NCT04641702 | Mar 2021 → Sep 2026 expected | achalasia | Emory University | Recruiting | No outcome recorded |
| Phase 4 | NCT05449015 | Dec 2020 → Mar 2023 | cycloplegia, myopia | Shanghai Eye Disease Prevention and Treatment Center | Unknown | No outcome recorded |
| Phase 4 | NCT03984526 | Jun 2019 → Sep 2020 | — | Ajou University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03949101 | May 2019 → May 2021 | myopia | Shanghai Eye Disease Prevention and Treatment Center | Unknown | No outcome recorded |
| Phase 4 | NCT03638726 | Sep 2018 → Mar 2019 | cataract | Dar El Oyoun Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03544827 | May 2018 → Feb 2019 | myopia | State University of New York College of Optometry | Completed | No outcome recorded |
| Phase 4 | NCT03158142 | Mar → Nov 2017 | myopia | State University of New York College of Optometry | Completed | No outcome recorded |
| Phase 4 | NCT02769325 | May 2016 → May 2017 | — | Clinica Santa Maria | Unknown | No outcome recorded |
| Phase 4 | NCT02522858 | Aug 2015 → Jan 2016 | — | Sira Bang | Completed | No outcome recorded |
| Phase 4 | NCT01819064 | Feb → Jul 2013 | cardiac rhythm disease | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 4 | NCT01845636 | Aug 2012 → Mar 2016 | cognitive impairment with or without cerebellar ataxia | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT02186132 | Mar 2012 → Feb 2013 | curariform drugs toxicity | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT00834470 | Aug 2008 → Dec 2010 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00921102 | May 2007 → Feb 2008 | — | University of Parma | Completed | No outcome recorded |
| Phase 4 | NCT00541177 | Apr 2007 → Mar 2008 | myopia | Min-Sheng General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00094614 | Jun 2002 → Apr 2003 | amblyopia | Jaeb Center for Health Research | Completed | No outcome recorded |
| Phase not applicable28 trials | ||||||
| — | NCT07537166 | Apr → Dec 2026 expected | — | China Medical University Hospital | Enrolling by invitation | No outcome recorded |
| — | NCT07475585 | Mar 2026 → Jul 2027 expected | myopia | Fangbiao Tao | Not yet recruiting | No outcome recorded |
| — | NCT07364370 | Feb 2026 → Aug 2027 expected | early-onset non-syndromic cataract, myopia | Cairo University | Not yet recruiting | No outcome recorded |
| — | NCT07176949 | Jun 2025 → Jun 2027 expected | myopia | Shanghai Eye Disease Prevention and Treatment Center | Recruiting | No outcome recorded |
| — | NCT06667037 | Sep 2024 → Dec 2026 expected | myopia | Zhongshan Ophthalmic Center, Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT06358755 | Jul 2024 → May 2026 overdue | myopia | The Hong Kong Polytechnic University | Active not recruiting | No outcome recorded |
| — | NCT05379855 | Mar 2024 → Feb 2027 expected | exotropia, myopia | Eye & ENT Hospital of Fudan University | Recruiting | No outcome recorded |
| — | NCT06071260 | Dec 2023 | myopia | He Eye Hospital | Unknown | No outcome recorded |
| — | NCT06034379 | Oct 2023 → Dec 2025 overdue | myopia | Kubota Vision Inc. | Recruiting | No outcome recorded |
| — | NCT06034366 | Oct 2023 → May 2025 | myopia | He Eye Hospital | Unknown | No outcome recorded |
| — | NCT06727019 | Apr → Sep 2023 | myopia | Beijing Tongren Hospital | Completed | No outcome recorded |
| — | NCT05939882 | Apr 2023 → Apr 2024 | myopia | Shanghai Eye Disease Prevention and Treatment Center | Unknown | No outcome recorded |
| — | NCT05597163 | Jan 2023 → Nov 2024 | myopia | Shanghai Eye Disease Prevention and Treatment Center | Unknown | No outcome recorded |
| — | NCT05560542 | Oct 2022 → Mar 2025 | poisoning | Assiut University | Completed | No outcome recorded |
| — | NCT04699357 | Jul 2021 → Aug 2024 | myopia | Shanghai Eye Disease Prevention and Treatment Center | Completed | No outcome recorded |
| — | NCT04625088 | Mar → Aug 2021 | — | SciMar Ltd. | Completed | No outcome recorded |
| — | NCT04777383 | Apr 2019 → Oct 2021 | vascular disorder | University Hospital, Linkoeping | Terminated | No outcome recorded |
| — | NCT03374306 | Feb 2018 → Dec 2019 | myopia | The Hong Kong Polytechnic University | Completed | No outcome recorded |
| — | NCT02955927 | Nov 2016 → May 2021 | myopia | The Hong Kong Polytechnic University | Completed | No outcome recorded |
| — | NCT02927223 | Oct 2016 → Feb 2019 | catecholaminergic polymorphic ventricular tachycardia | Vanderbilt University | Completed | No outcome recorded |
| — | NCT03312257 | Jul 2016 → Jun 2020 | refractive error | Jenny Jones | Completed | No outcome recorded |
| — | NCT03839888 | Jan → Dec 2015 | myopia | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | Completed | No outcome recorded |
| — | NCT03402100 | Oct 2014 → Dec 2019 | drug pseudoallergy, myopia | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| — | NCT02130167 | Aug 2012 → Jul 2017 | myopia | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT01464489 | May → Sep 2011 | — | Gachon University Gil Medical Center | Completed | No outcome recorded |
| — | NCT02055378 | Jan 2011 → Dec 2012 | myopia | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | Completed | No outcome recorded |
| — | NCT00320892 | Jan 2007 → Dec 2009 | — | Soroka University Medical Center | Terminated | No outcome recorded |
| — | NCT00328900 | Jan 2006 → ? | hemorrhoid, ulcer of anus and rectum | Rikshospitalet University Hospital | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 135 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03328312 Comparator | Dec 2017 → Mar 2018 | curariform drugs toxicity | Iuliu Hatieganu University of Medicine and Pharmacy | Unknown | No outcome recorded |
| Phase 110 trials | ||||||
| Phase 1 | NCT06787638 Comparator | Jan 2025 → Jan 2026 overdue | — | Aswan University Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06982092 Comparator | Aug 2024 → Jan 2025 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT06029530 Comparator | Jan → Aug 2024 | myopia | Ohio State University | Withdrawn | No outcome recorded |
| Phase 1 | NCT04290039 Comparator | Jan → Feb 2020 | poisoning | Biomedical Advanced Research and Development Authority | Completed | No outcome recorded |
| Phase 1 | NCT03718507 Background | May → Dec 2019 | newborn respiratory distress syndrome | ASST Fatebenefratelli Sacco | Withdrawn | No outcome recorded |
| Phase 1 | NCT03690414 Comparator | Oct 2018 → Feb 2019 | myopia | Hai Yen Eye Care | Completed | No outcome recorded |
| Phase 1 | NCT03699423 Comparator | Mar → Apr 2018 | myopia | Hai Yen Eye Care | Completed | No outcome recorded |
| Phase 1 | NCT00947596 Comparator | Aug 2009 → Jul 2010 | organophosphate poisoning | MicroDose Defense Products L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT00468091 Comparator | Feb 1999 → Sep 2000 | endocrine pancreas disorder, intestinal motility disease | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 1 | NCT00748059 Background | Dec 1996 → Dec 2020 | autonomic nervous system disorder, disorder of catecholamine synthesis, orthostatic hypotension | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06729047 Comparator | Dec 2024 → Nov 2025 overdue | intracranial hypotension | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06794450 Comparator | Nov 2024 → Feb 2025 overdue | curariform drugs toxicity | Padjadjaran University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05372991 Comparator | Jul 2022 → Jan 2023 | myopia | Cloudbreak Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT02858310 Background | Jan 2017 → Jul 2025 | cervical intraepithelial neoplasia, human papilloma virus infection, in situ carcinoma, vulvar neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT07456488 Comparator | Jul 2025 → Apr 2026 overdue | — | Liaquat National Hospital & Medical College | Recruiting | No outcome recorded |
| Phase 2 | NCT06579287 Comparator | Jan 2025 → Dec 2026 expected | myopia | Sunhawk Vision Biotech, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06265454 Comparator | Sep 2024 → Dec 2025 | myopia | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT06327399 Comparator | Apr → Aug 2024 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 2 | NCT06111352 Background | Jun 2022 → Sep 2023 | organophosphate poisoning | Sir Salimullah Medical College Mitford Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04347486 Comparator | Apr 2020 → Dec 2021 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03943888 Comparator | Aug 2019 → Feb 2020 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02839668 Background | Aug 2016 → Sep 2019 | breast cancer | Iuliu Hatieganu University of Medicine and Pharmacy | Completed | No outcome recorded |
| Phase 2 | NCT02676011 Comparator | Feb → May 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02622126 Comparator | Jan → Jul 2016 | blood coagulation disease | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02704923 Comparator | Feb → Dec 2015 | — | Universidade de Passo Fundo | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT04393103 Background | Apr 2024 → Jan 2025 | organophosphate poisoning | Amani Hassan Abdel-Wahab | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02700893 Comparator | Mar → Aug 2016 | cerebrovascular disorder | Centre Hospitalier Intercommunal Creteil | Completed | No outcome recorded |
| Phase 2/3 | NCT02752308 Comparator | Sep 2014 → Mar 2015 | hypospadias | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT01490580 Background | May 2012 → Aug 2016 | — | Centre Hospitalier Intercommunal Creteil | Completed | No outcome recorded |
| Phase 322 trials | ||||||
| Phase 3 | NCT07271875 Comparator | Jan 2026 → Nov 2027 expected | ileus, intestinal dysmotility syndrome | Xijing Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07329777 Comparator | Sep 2025 → Sep 2027 expected | myopia | IDB VisionCare SDN BHD | Recruiting | No outcome recorded |
| Phase 3 | NCT06389110 Comparator | Mar 2025 → Oct 2027 expected | myopia | Laboratorios Sophia S.A de C.V. | Recruiting | No outcome recorded |
| Phase 3 | NCT06708156 Comparator | Jun 2024 → Dec 2026 expected | myopia | Oupushifang Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07626892 Comparator | Jun 2024 → May 2026 | myopia | Khyber Medical College, Peshawar | Completed | No outcome recorded |
| Phase 3 | NCT05658380 Comparator | Dec 2022 → May 2023 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT05667454 Comparator | Dec 2022 → Mar 2029 expected | myopia | Erasmus Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT06209320 Comparator | Mar 2022 → Mar 2025 overdue | myopia | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03140358 Comparator | Apr 2017 → Dec 2024 overdue | myopia | Singapore National Eye Centre | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02160548 Comparator | Apr → Dec 2015 | organophosphate poisoning | Sylhet M.A.G.Osmani Medical College | Completed | No outcome recorded |
| Phase 3 | NCT02658721 Background | Jan → Jun 2013 | — | Bagcilar Training and Research Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01422304 Background | Oct 2011 → Sep 2012 | blood coagulation disease, osteoarthritis, hip, osteoarthritis, knee | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01809886 Background | Oct 2011 → Oct 2013 | — | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | Completed | No outcome recorded |
| Phase 3 | NCT00944710 Comparator | Aug 2009 → Oct 2013 | amblyopia | Jaeb Center for Health Research | Completed | No outcome recorded |
| Phase 3 | NCT01858090 Comparator | Jan → Oct 2009 | — | Baskent University | Completed | No outcome recorded |
| Phase 3 | NCT00724932 Background | Jul 2008 → Apr 2009 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00623207 Comparator | Dec 2007 → Oct 2009 | intermediate coronary syndrome | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| Phase 3 | NCT00506675 Comparator | Oct 2007 → Apr 2009 | amblyopia | Jaeb Center for Health Research | Terminated | No outcome recorded |
| Phase 3 | NCT00315328 Comparator | Aug 2005 → Dec 2007 | amblyopia | Jaeb Center for Health Research | Completed | No outcome recorded |
| Phase 3 | NCT00315302 Comparator | Feb 2005 → Oct 2007 | amblyopia | Jaeb Center for Health Research | Completed | No outcome recorded |
| Phase 3 | NCT00313872 Background | May 2003 → Jun 2009 | gastric cancer, metastatic neoplasm | Samsung Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00000170 Comparator | Apr 1999 → Nov 2001 | amblyopia | Jaeb Center for Health Research | Completed | No outcome recorded |
| Phase 437 trials | ||||||
| Phase 4 | NCT07666984 Comparator | Jun → Jul 2026 overdue | — | Cukurova University | Recruiting | No outcome recorded |
| Phase 4 | NCT07268586 Comparator | Aug 2025 → Feb 2026 | myocardial infarction | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT06493838 Comparator | Jul 2024 → Jan 2025 overdue | — | Minia University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06081738 Comparator | Mar → Sep 2023 | — | Menoufia University | Unknown | No outcome recorded |
| Phase 4 | NCT05006638 Comparator | Dec 2022 → Jun 2023 | poisoning | Aya Sabry Mohamed Mohamed | Unknown | No outcome recorded |
| Phase 4 | NCT05331664 Comparator | Jul 2022 → Jul 2026 overdue | rhegmatogenous retinal detachment | Massachusetts Eye and Ear Infirmary | Recruiting | No outcome recorded |
| Phase 4 | NCT06431841 Background | Feb 2022 → Jun 2025 overdue | myopia | Hospital San Carlos, Madrid | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05037006 Background | Oct → Dec 2021 | curariform drugs toxicity | Pontifical Catholic University of São Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT06266962 Comparator | Jul 2020 → Sep 2022 | intraoperative floppy iris syndrome, senile cataract | University Hospital Olomouc | Completed | No outcome recorded |
| Phase 4 | NCT03909165 Comparator | Jul 2019 → Sep 2023 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT03932578 Comparator | May → Aug 2019 | — | Mansoura University | Completed | No outcome recorded |
| Phase 4 | NCT04365686 Background | Apr 2019 → Apr 2020 | — | Fayoum University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03997006 Comparator | Jan 2019 → Jan 2020 | intracranial hypotension | Damanhour Teaching Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03351608 Comparator | Feb 2018 → Jan 2020 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT03580889 Comparator | Sep 2017 → Sep 2018 | — | B.P. Koirala Institute of Health Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT03034577 Comparator | Jun 2017 → Feb 2019 | — | University of Melbourne | Completed | No outcome recorded |
| Phase 4 | NCT03144453 Comparator | May 2017 → Dec 2019 | — | Regina Elena Cancer Institute | Unknown | No outcome recorded |
| Phase 4 | NCT02648503 Comparator | Mar → Sep 2016 | neuromuscular disease | University of Medicine and Pharmacy at Ho Chi Minh City | Unknown | No outcome recorded |
| Phase 4 | NCT02410590 Comparator | Jul 2015 → Oct 2016 | — | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 4 | NCT02455921 Comparator | Jun 2015 → Mar 2018 | — | Attikon Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02361060 Comparator | Feb 2015 → Jul 2016 | — | Enrique Alday Muñoz | Completed | No outcome recorded |
| Phase 4 | NCT02256280 Comparator | Jan 2015 → Mar 2020 | — | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Terminated | No outcome recorded |
| Phase 4 | NCT02327923 Comparator | Jan 2015 → Feb 2016 | gallstones | B.P. Koirala Institute of Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02698969 Comparator | Nov 2014 → Feb 2017 | curariform drugs toxicity | University of Florence | Unknown | No outcome recorded |
| Phase 4 | NCT02215382 Comparator | Aug → Oct 2014 | ocular hypotension | Ordu University | Completed | No outcome recorded |
| Phase 4 | NCT02286752 Background | Jun 2014 → Jan 2015 | — | Ordu University | Completed | No outcome recorded |
| Phase 4 | NCT02445599 Background | Apr 2014 → Apr 2016 | lung disorder | University of Debrecen | Completed | No outcome recorded |
| Phase 4 | NCT02078336 Comparator | Dec 2013 → Jul 2025 overdue | — | Universitaire Ziekenhuizen KU Leuven | Active not recruiting | No outcome recorded |
| Phase 4 | NCT01761552 Comparator | Aug 2013 → Dec 2015 | — | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 4 | NCT01718236 Background | Sep 2012 → Jan 2015 | pregnancy disorder | Brno University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02512055 Background | May 2012 → May 2014 | — | Baskent University | Completed | No outcome recorded |
| Phase 4 | NCT01595399 Comparator | Apr 2012 → Jun 2014 | — | University of Manitoba | Unknown | No outcome recorded |
| Phase 4 | NCT01539044 Comparator | Feb 2012 → Jun 2013 | curariform drugs toxicity | Hospital Sultanah Aminah Johor Bahru | Completed | No outcome recorded |
| Phase 4 | NCT01427985 Comparator | Jun 2011 → Jul 2012 | — | University of Ulm | Completed | No outcome recorded |
| Phase 4 | NCT00991627 Background | Sep 2009 → Aug 2010 | hypotensive disorder, pregnancy disorder | University of Parma | Completed | No outcome recorded |
| Phase 4 | NCT00815048 Comparator | Jan 2006 → Feb 2008 | — | King Saud University | Completed | No outcome recorded |
| Phase 4 | NCT00575523 Comparator | Oct 2003 → Jan 2008 | acute respiratory failure, cardiac rhythm disease | Medical University of Vienna | Completed | No outcome recorded |
| Phase not applicable46 trials | ||||||
| — | NCT07524959 Background | May → Jul 2026 overdue | — | Beijing Tongren Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07309393 Background | Dec 2025 → Sep 2026 expected | — | Shanghai Pulmonary Hospital, Shanghai, China | Recruiting | No outcome recorded |
| — | NCT07129889 Comparator | Dec 2025 → Jun 2027 expected | myopia | Ningbo Eye Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07253428 Background | Oct → Dec 2025 overdue | nasal disorder | Ain Shams University | Active not recruiting | No outcome recorded |
| — | NCT07092046 Comparator | Aug 2025 | — | Ankara City Hospital Bilkent | Completed | No outcome recorded |
| — | NCT06922097 Comparator | Apr → Nov 2025 | — | University of Hamburg-Eppendorf | Completed | No outcome recorded |
| — | NCT07614113 Comparator | Feb 2025 → Apr 2026 | myopia | University of Faisalabad | Completed | No outcome recorded |
| — | NCT06678451 Comparator | Dec 2024 → May 2025 overdue | — | Shanxi Bethune Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06436768 Comparator | Jun 2024 → Mar 2025 | — | Beijing Tongren Hospital | Completed | No outcome recorded |
| — | NCT07519226 Comparator | May 2024 → Mar 2026 | — | Lihua Wen | Completed | No outcome recorded |
| — | NCT06282848 Comparator | Jan 2024 → Dec 2026 expected | myopia | The Hong Kong Polytechnic University | Recruiting | No outcome recorded |
| — | NCT06082388 Comparator | Nov 2023 → Sep 2025 | cardiac rhythm disease | Medical University of Lodz | Unknown | No outcome recorded |
| — | NCT06344429 Comparator | Aug 2023 → Aug 2024 | myopia | Essilor-Polylite Taiwan Co., Ltd. | Unknown | No outcome recorded |
| — | NCT05825430 Background | Apr → Jun 2023 | — | Al-Azhar University | Completed | No outcome recorded |
| — | NCT06210165 Comparator | Dec 2022 → Jun 2024 | pulmonary immaturity | Rhendra Hardy Mohamad Zaini | Unknown | No outcome recorded |
| — | NCT05478356 Comparator | Aug 2022 → Aug 2023 | myopia | Evidence Based Cataract Study Group | Unknown | No outcome recorded |
| — | NCT05203432 Comparator | Feb 2022 → Jun 2024 | myopia | Shanghai Eye Disease Prevention and Treatment Center | Unknown | No outcome recorded |
| — | NCT05137288 Comparator | Dec 2021 → May 2022 | — | Sohag University | Unknown | No outcome recorded |
| — | NCT05062031 Comparator | Oct 2021 → Feb 2026 overdue | myopia | Fondation Ophtalmologique Adolphe de Rothschild | Active not recruiting | No outcome recorded |
| — | NCT04950881 Background | Jul 2021 → Dec 2022 | — | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Unknown | No outcome recorded |
| — | NCT04274413 Background | Feb 2021 | CFTR-related disorder, cystic fibrosis | The Hospital for Sick Children | Withdrawn | No outcome recorded |
| — | NCT04566796 Comparator | Aug 2020 → Feb 2021 | — | Alexandria University | Unknown | No outcome recorded |
| — | NCT04258007 Comparator | Jan → Nov 2020 | — | Mansoura University | Completed | No outcome recorded |
| — | NCT04505228 Background | Jan → Mar 2020 | hypertensive heart disease | Jun Xiao | Completed | No outcome recorded |
| — | NCT06609993 Background | Dec 2017 → Mar 2020 | abdominal aortic aneurysm | Michał Stasiowski | Completed | No outcome recorded |
| — | NCT03322098 Comparator | Oct 2017 → May 2018 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT03322150 Comparator | Oct 2017 → Aug 2018 | — | Yonsei University | Terminated | No outcome recorded |
| — | NCT04612998 Comparator | Feb 2017 → Mar 2018 | hypotensive disorder, local anesthetic poisoning, obesity disorder, pregnancy disorder | Ataturk University | Completed | No outcome recorded |
| — | NCT02726620 Background | Jan → Dec 2017 | hypotensive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT02939430 Comparator | Nov 2016 → Oct 2017 | — | Mansoura University | Unknown | No outcome recorded |
| — | NCT02944175 Comparator | Jul 2016 → Sep 2019 | supratentorial cancer | Mansoura University | Unknown | No outcome recorded |
| — | NCT02743104 Comparator | May 2016 → May 2019 | — | Rabin Medical Center | Suspended | No outcome recorded |
| — | NCT02546843 Comparator | Dec 2015 → Sep 2018 | — | Brno University Hospital | Completed | No outcome recorded |
| — | NCT04500249 Background | Oct 2015 → Oct 2020 | carotid stenosis | Medical University of Silesia | Unknown | No outcome recorded |
| — | NCT02310789 Background | Jul 2015 → Aug 2016 | cystic fibrosis | Richard Barry Moss | Completed | No outcome recorded |
| — | NCT07033442 Comparator | Jul → Nov 2015 | ocular hypertension | Ataturk Training and Research Hospital | Completed | No outcome recorded |
| — | NCT02228473 Comparator | Sep 2014 → Feb 2015 | urinary bladder neoplasm | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT02213848 Background | Aug → Oct 2014 | curariform drugs toxicity | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT02931786 Comparator | Aug 2014 → Feb 2015 | — | Istanbul University | Completed | No outcome recorded |
| — | NCT02633579 Comparator | Oct 2012 → Aug 2014 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| — | NCT01871922 Comparator | Oct 2012 → Jun 2013 | — | University Medical Center Groningen | Completed | No outcome recorded |
| — | NCT01534442 Comparator | Sep 2011 → Dec 2012 | — | University Hospital, Gentofte, Copenhagen | Unknown | No outcome recorded |
| — | NCT02419352 Comparator | Sep 2010 → Dec 2015 | — | Attikon Hospital | Completed | No outcome recorded |
| — | NCT01191398 Comparator | Jun 2010 → Jan 2011 | — | Craig J. Huang | Completed | No outcome recorded |
| — | NCT00998205 Background | Jun 2008 → Jan 2011 | diastolic heart failure | University of Missouri-Columbia | Completed | No outcome recorded |
| — | NCT00608725 Background | Dec 1996 → Dec 2029 expected | cardiac rhythm disease, postural orthostatic tachycardia syndrome | Satish R. Raj | Active not recruiting | No outcome recorded |
Evidence & citations 50 cited values
Every value below carries the sentence it was read from. 243 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atropine | “The overall development plan is to show that the combination of tried-and-proven decongestant/antihistamine ingredients (pseudoephedrine hydrochloride and chlorpheniramine...” NCT01293201 ↗216“Neostigmine (0.03 mg/kg) combined with atropine (0.015 mg/kg) is administered intravenously for reversal of rocuronium-induced neuromuscular blockade at the end of unilateral...” NCT07309393 ↗ “Prophylactic Intravenous Injection of Neostigmine Plus Atropine Versus Ketorolac on Post-dural Puncture Headache in Patients Undergoing Infraumbilical Surgeries: A Randomized...” NCT06729047 ↗ “To assess the safety and efficacy of NVK002 (Vyluma), a novel, preservative-free, 0.01% and 0.02% low-dose atropine formulation for treating myopia progression.” PMID 37261839 ↗ Oct 2023 “Patients will receive 0.02 mg/ kg atropine and 0.04 mg/ kg neostigmine following observing the second response on stimulating the ulnar nerve on the TOF watch” NCT04258007 ↗ “patients in this group will receive 0.02 mg/kg atropine with neostigmine 0.05 mg/kg IV. to reverse the action of the neuromuscular blocker given.” NCT04566796 ↗ “The CHAMP UK study is investigating a type of eye drop called atropine that might help to stop myopia getting worse as children get older.” NCT03690089 ↗ “When T2 appeared, the neostigmine group was given 0.04mg/kg of neostigmine + 0.02mg/kg of atropine intravenously (adjusted body weight).” NCT06678451 ↗ “The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over” NCT01809886 ↗ “Oral tablet containing Pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, atropine sulfate .24mg, one tablet BID.” NCT00932256 ↗ “a dose of 50 ug/kg neostigmine (up to 5 mg maximum dose) plus atropine 0.02 mg/kg (up to 2 mg maximum dose) was administered.” NCT06436768 ↗ “rescue intravenous antihypotensive medication using 500 mcg of atropine will be administered by anaesthesiologist” NCT04500249 ↗ “atropine (0.01-0.02mg/kg) or isoproterenol (1-2 μg/per time)is given intravenously to increase the heart rate.” NCT04950881 ↗ “Atropine sulfate 0.24 mg white, scored, tablets with "M27" on scored side and plain on the other side” NCT02082054 ↗ “Neostigmine 50 micrograms/kg coupled with atropine 20 micrograms/kg or glycopyrrolate 5 micrograms/kg” NCT03034577 ↗ “reversal of the patients was done by injection of neostigmine 0.05mg\\ kg and atropine 0.01mg\\kg.” NCT04365686 ↗ “Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg” NCT02213848 ↗ “Neostigmine will be diluted with atropine in a saline water solution in a 10 mL syringe.” NCT02256280 ↗ “Cocktail composed of atropine (280µM), isoproterenol (160µM), and aminophylline (20 mM).” NCT02310789 ↗ “Patients in the NEO Group will receive 50 mic/kg neostigmine and .01-.02 mg/kg atropine” NCT06982092 ↗ “Under the first probe, injection atropine will be given in one small area of the skin.” NCT04274413 ↗ “for reversal of neuromuscular block: 0,05 mg kg-1 neostigmine + 0,025 mg kg-1 atropine” NCT02286752 ↗ “Using rocuronium and reversal with neostigmine (1 to 2 mg) and atropine (0.5 to 1 mg)” NCT02648503 ↗ “All patients aged between 6 months-10 years were administered midazolam and atropine.” NCT02931786 ↗ “atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes)” NCT03718507 ↗ “Administer neostigmine at a dose of 0.04 mg/kg (combined with 0.02 mg/kg atropine)” NCT07524959 ↗ “full dose of Neostigmine (0.08 mg/kg) plus Atropine (20 mic/kg+7ml normal saline)” NCT06787638 ↗ “neostigmine 0.05 mg·kg-1 + atropine 0.02 mg·kg-1 was administered intravenously” NCT02944175 ↗ “Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine” NCT04347486 ↗ “diphenoxylate/atropine 5mg/0.05mg (Lomotil) decreases bowel activity” NCT00583323 ↗ “Atropine (anti-muscarinic drug; G-Atropine) by intravenous route” NCT02160548 ↗ “0.04 mg/kg neostigmine with 0.01 mg/kg atropine intravenously” NCT06081738 ↗ “neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously” NCT02546843 ↗ “Neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOFc 3” NCT05037006 ↗ “neostigmine 50 micg/kg + atropine 20 micg /kg i.v.” NCT05825430 ↗ “children who received 0.01% atropine for myopia” NCT03402100 ↗ “receive ketamine 2 mg/kg and atropine 10 μg/kg” NCT02512055 ↗ “atropine 0.01 mg/kg and neostigmine 0.03 mg/kg” NCT01718236 ↗ “Atropine 0.04 mg/kg IV in divided doses” NCT00608725 ↗ “D1 atropine 0.3mg SQ before irinotecan” NCT00313872 ↗ “Low-concentration Atropine Eye Drops” NCT06523504 ↗ “Atropine and neostigmine” NCT03943888 ↗ “0.01% atropine eye drops” NCT07129889 ↗ “Atropine” NCT05892913 ↗ |
| Known as | Alleance | “Alleance®. Atropine sulfate 0.01%. Ophthalmic solution.” NCT06389110 ↗ |
| Known as | ATR | “atropine (ATR) + clamp (CLA) + MSF” PMID 26492921 ↗ Oct 2015 |
| Known as | Atroject | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropen | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atrophate | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine (autoinjector) | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine component of atnaa | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine component of duodote | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine gel, mucoadhesive atropine gel | “Atropine gel, mucoadhesive atropine gel” NCT05164367 ↗ |
| Known as | atropine sulfate | “OBJECTIVE: To compare weekend atropine sulfate use augmented by a plano lens for the sound eye with weekend atropine use alone for moderate amblyopia in children aged 3 years...” PMID 19139333 ↗ Jan 200928“Topical atropine sulfate ophthalmic solution 0.01% administered as one drop in each eye once daily at bedtime for 18 months for control of myopia progression in children.” NCT07626892 ↗ “three low-concentration atropine sulfate eye drops (0.01%, 0.025% and 0.05%)” NCT05597163 ↗ “Atropine Sulfate 0.05% Oph Soln compounded at the pharmacy” NCT07567040 ↗ “Two drops of 0.01% atropine sulfate solution” NCT07674966 ↗ “Atropine sulfate 0.01%, ophthalmic solution.” NCT06389110 ↗ “OT-101 (Atropine Sulfate 0.01%)” NCT04770610 ↗ “Drug: Atropine sulfate 0.01%” NCT03140358 ↗ “Atropine sulfate gel (0.01%)” NCT05164367 ↗ “Atropine sulfate” NCT05855018 ↗ |
| Known as | Atropine sulfate anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate ansyr plastic syringe | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of colonaid | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of di-atro | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of enlon-plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of lo-trol | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of logen | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of lomanate | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of lomotil | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of lonox | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of low-quel | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of motofen | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate injection | “Atropine sulfate injection is indicated for temporary blockade of severe or life-threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for...” NCT04290039 ↗ |
| Known as | Atropine sulfate lifeshield abboject syringe | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate ophthalmic solution | “Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia.” NCT04290039 ↗ |
| Known as | Atropine Sulphate | “with morphine 250mic and atropine sulphate 100 micwith total volume = 2.5 ml” NCT05137288 ↗4“The atropine eye drops contain 0.01% atropine sulphate.” NCT03690089 ↗ “Atropine Sulphate 0.025% w/v Eye Drops” NCT07329777 ↗ |
| Known as | atropinehydrochloride | “Patients scheduled for PEI were randomized 1:1 to receive 0.5 mg atropinehydrochloride or placebo in a double-blind randomized placebo-controlled trial.” PMID 19018977 ↗ Oct 2008 |
| Known as | Atropini sulfas | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropinum Sulfuricum WZF | “atropine (Atropinum Sulfuricum WZF, POlfa Warsawa, Poland) in a dose of 0,5mg/kg of will be administered intravenously” NCT06609993 ↗ |
| Known as | Atropinum sulphuricum | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropisol | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropt | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Dl-hyoscyamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Isopto atropine | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | NSC-26671 | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | NSC-755889 | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | OT-101 | “OT-101 (Atropine Sulfate 0.01%)” NCT04770610 ↗ |
| Known as | PRO-201 | “Evaluation of the safety and tolerability of PRO-201 (0.01% sulfate atropine) after its instillation on the ocular surface of healthy volunteers through the following...” NCT05470881 ↗ |
| Known as | SYD-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03918915 ↗ |
| Known as | Xingqi Meioupin | “Initial treatment: 1 time per night, apply 0.01% atropine eye drops to both eyes (brand name: Xingqi Meioupin, Xingqi Pharmaceutical, 30 drops per box).” NCT07475585 ↗ |
| Action | Inhibit | “acts as an antagonist on the muscarinic receptors of the sweat glands and inhibits their secretion” NCT00328900 ↗3“Muscarinic acetylcholine receptor M1 antagonist” CHEMBL517712 ↗ “Muscarinic acetylcholine receptor M2 antagonist” CHEMBL517712 ↗ “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL517712 ↗ |
| Modality | Other / unclassified | “Atropine is an anticholinergic agent” NCT05658380 ↗ |
| Route | Intravenous | “Atropine 3 mg iv in initial systole” NCT00121524 ↗ |
| Target | CHRM1 | “Muscarinic acetylcholine receptor M1 antagonist” CHEMBL517712 ↗ |
| Target | CHRM2 | “Muscarinic acetylcholine receptor M2 antagonist” CHEMBL517712 ↗ |
| Target | CHRM3 | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL517712 ↗ |